In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


McGaw Inc.

Division of B. Braun Melsungen AG

Latest From McGaw Inc.

On FDA Letter, B. Braun Sees the Door Open

With the FDA warning hospitals not to use IV solution bags made of PVC-based materials, B. Braun officials hope they may finally see the US IV market open to them.

Medical Device Business Strategies

Beyond Bypass: Next Generation Coronary Revascularization

Traditional coronary artery bypass graft (CABG) surgery has been refined to be the most effective long-term treatment for occluded coronary arteries. Yet it remains a major surgical procedure that is traumatic for patients. Various minimally-invasive approaches to cardiac surgery have been developed but adoption rates are slow because these new procedures don't yet measure up to traditional CABG and because heart surgeons are slow adopters of new technology. Recent discoveries in coronary physiology have opened the door for new approaches to creating cardiac perfusion in a patient with occluded vessels. But this requires physicians to re-think what they were taught in medical school. One such approach, which involves direct vascularization from the ventricle, is being pursued by three companies: Percardia, HeartStent and Ventrica. Another company, TransVascular, is taking a broader approach by using the venous system to bypass arterial blockages. Approaches that require physicians to think differently about basic science, along with the tortuous clinical and regulatory path for new cardiac surgery devices and the cautious nature of cardiothoracic surgeons, present significant challenges to these start-up companies.

Medical Device Business Strategies

Aesculap: From Products to Process

Like its parent company, B. Braun, Aesculap has built a business around a broad-based offering of products, in this case general and specialty surgical instruments and devices and orthopedic implants. Such a strategy enables Aesculap to leverage everything from product development to sales and marketing. But now, as Aesculap seeks to extend such leveraging to collaborations with its parent company, the company walks a fine line between exploiting natural synergies without sacrificing the focus that made it successful in the first place.

Medical Device Clinical Trials

CardioNet Inc.

Entrepreneur Jim Sweeney, credited with founding the home infusion therapy industry, heads up CardioNet Inc., a start-up that aims to provide real-time cardiac monitoring, so patients can get prompter treatment. The CardioNet system senses and transmits cardiac events automatically, an important feature, since 40% of heart attack victims aren't even aware that they are experiencing some form of life-threatening event.

Medical Device
See All

Company Information

  • Industry
  • Medical Devices
  • Pharmaceuticals
    • Drug Delivery
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • B. Braun Melsungen AG
  • Senior Management
  • Norwick Goodspeed, CEO
    Sterling Blanchard, VP
  • Contact Info
  • McGaw Inc.
    Phone: (949) 660-2000
    2525 McGaw Avenue
    P.O. Box 19791 Irvine, CA 92614